Article Text

Download PDFPDF

323 TALEN®-based gene edited iPSC-derived NK (iNK) cells demonstrate enhanced antitumor activity
  1. An-Ping Chen1,
  2. Peng Gao1,
  3. Preeti Ashok1,
  4. Marshall Chao Ma1,
  5. David Zou1,
  6. Andrea Chambers1,
  7. Liang Lin1,
  8. Hao-Ming Chang1,
  9. Antonio Arulanandam1,
  10. Justin Eyquem2,
  11. Elisabetta Burchi1,
  12. Armin Rath1,
  13. Stanley Frankel1,
  14. Alex Boyne3,
  15. Alexandre Juillerat3,
  16. Philippe Duchateau4,
  17. Daniel Teper1,
  18. Nejmi Dilmac1 and
  19. Wei Li1
  1. 1Cytovia Therapeutics, Natick, MA, USA
  2. 2University of California San Francisco, San Francisco, CA, USA
  3. 3Cellectis Inc., New York, NY, USA
  4. 4Cellectis Inc., Paris, France


Background Natural killer (NK) cell therapies have shown a great promise for solid and liquid tumors in initial clinical trials. NK cells are innate immune cells with distinct potential safety and efficacy advantages compared to adoptive T-cell therapies. However, there are limitations with the persistence and immunosuppression of these cells in the tumor microenvironment. Furthermore, multiple sources of NK cells have been used in clinical trials and there are challenges with manufacturing homogeneous and high doses of these cells. Induced Pluripotent Stem Cell (iPSC)-derived NK cells offer an opportunity to generate unlimited and homogenous NK cells for allogeneic off-the-shelf therapies. We combined Cytovia’s iNK cell platform with Cellectis TALEN® gene editing technology to improve potency and the manufacturing process. Clonally edited iPSC lines were generated by knocking in IL-15 and knocking out TGFβR2 to improve the persistence and antitumor activity, respectively. Edited iPSCs were differentiated into iNK cells with high efficiency using Cytovia’s proprietary platform.

Methods iPSCs were edited at the B2M locus with TALEN® pairs along with a template to knock in IL-15 by electroporation. Another TALEN® pair was sequentially used to knock out TGFβR2. Edited single cell iPSCs were printed, expanded, and screened for clone selection. Selected clones were sequence verified by NGS and samples were submitted for off-target assessment by GUIDE-seq. Expression of IL-15 and TGFβR2 was measured by ELISA and western blot, respectively. iPSCs were differentiated into iNK cells and analyzed by surface staining and flow cytometry. Cytotoxicity assay was performed against K562 tumor cells.

Results Several single and double gene edited iPSC lines were generated with high efficiency to produce NK cells: iPSC-IL-15 (+/+), iPSC-TGFβR2 (-/-) and iPSC-IL-15 (+/+)-TGFβR2 (-/-). These TALEN®-edited iPSCs kept their pluripotency, exhibited normal morphology and karyotype with no detected off-target effect. Edited iPSCs were differentiated into NK cells with high efficiency (CD56+/CD45+>95%) and enhanced cytotoxicity against K562 tumor cells compared to unedited iNK cells. Moreover, TGFβR2 protein was not detected, while the expression of secreted IL-15 was observed in the edited iNK cells confirming the phenotype of these cells.

Conclusions Cytovia’s iPSC-NK platform combined with TALEN® gene editing robustly and reliably generated single cell edited iPSC clones, which were expanded and differentiated into functionally improved iNK cells. The data indicated iNK cells edited with an IL-15 knock in and TGFβR2 knock out resulted in enhanced antitumor activity. The editing and manufacturing process will enable clinical evaluation of these product candidates.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.